← Back to Search

Monoclonal Antibodies

Rapid Infusion Isatuximab for Multiple Myeloma

Phase 2
Waitlist Available
Research Sponsored by Thomas Martin, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Study Summary

This study is evaluating whether a faster infusion of isatuximab may be safe for patients with multiple myeloma.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with reported grade 2 or higher infusion-related reactions (IRR)
Secondary outcome measures
Mean per-participant infusion duration

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (isatuximab)Experimental Treatment1 Intervention
Participants receive their first rapid infusion of isatuximab IV over 30 minutes. If a >=Grade 2 iRR occurs, then participants will revert to a SOC infusion time and be removed from the study. If a Grade 1 or no IRR occurs, then participants will receive another rapid infusion of 30 minutes. Participants will continue to receive RI and IRR assessment after each dose up to at least 6 doses or until a grade 2 or higher IRR occurs.

Find a Location

Who is running the clinical trial?

Thomas Martin, MDLead Sponsor
3 Previous Clinical Trials
145 Total Patients Enrolled
3 Trials studying Multiple Myeloma
145 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
Thomas Martin, MD 2021. "Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04802031.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top